Research Article
Cardiac Function in Long-Term Survivors of Childhood Lymphoma
Table 2
Lymphoma characteristics and treatment data of survivors by lymphoma subtype.
| Patient | Staging | Histology | ChemoTx | Irradiation | Total dose (cGy) | Mantle dose (cGy) |
| HL | | | | | | | 1 | 3B | NONE | MOPP | MANTLE | 1500 | 1500 | 2 | 2B | NS | MOPP | MANTLE | 3000 | 3000 | 3 | 2B | NS | MOPP | MANTLE | 4000 | 4000 | 4 | 1A | LP | MOPP | MANTLE | 2000 | 2000 | 5 | 2B | LP | MOPP | MANTLE | 4000 | 4000 | 6 | 3A | MC | MOPP/ABVD | TOT. NODAL | 1650 | 1500 | 7 | 1A | NS | MOPP | MANTLE | 2600 | 2800 | 8 | 2A | MC | MOPP/ABVD | MANTLE | 2000 | 2000 | 9 | 2B | MC | MOPP/ABVD | MANTLE,INV.Y.SPLEEN | 5800 | 4000 | 10 | 2A | NS | MOPP/ABVD | MANTLE | 1800 | 1800 | 11 | 3B | NS | MOPP/ABVD | MANTLE,PARAAORTIC | 8000 | 4000 | 12 | 2B | NS | MOPP/ABVD | MANTLE,INV.Y | 4000 | 4000 | 13 | 2B | MC | MOPP/ABVD | MANTLE | 3060 | 3060 | 14 | 3B | NS | MOPP | MANTLE,INV.Y,SPLEEN | 5100 | 2500 | 15 | 2A | NONE | MOPP | MANTLE,INV.Y | 8400 | 4400 | 16 | 2B-BULKY | MC | MOPP/ABVD | MANTLE | 2600 | 2600 | 17 | 3A | NS | MOPP/ABVD | MANTLE | 2600 | 2600 | 18 | 2A-BULKY | NS | MOPP/ABVD | MANTLE | 4000 | 4000 | 19 | 1A | NS | MOPP/ABVD | MINIMANTLE | 3600 | 3600 | 20 | 2A | NS | MOPP/ABVD | MANTLE | 3000 | 3000 | 21 | 3B | LD | MOPP | MANTLE,INV.Y | 8000 | 4000 | 22 | 2A | NS | MOPP | MANTLE | 4000 | 4000 | 23 | 1A | LP | NONE | MANTLE | 4000 | 4000 | 24 | 2A | NS | MOPP/ABVD | MANTLE | 2600 | 2600 | 25 | 2A | NS | NONE | MANTLE,PARAO,SPLEEN | 8000 | 4000 | 26 | 2B-BULKY | NS | MOPP/ABVD | MANTLE | 3000 | 3000 |
| Average | | | | | 3935 | 3152 |
| BL | | | | | | | 27 | NP | 6 | COMP | | 0 | 0 | 28 | ABD | 6 | NCI | | 0 | 0 | 29 | ABD | 6 | LMB | | 0 | 0 | 30 | ABD | 6 | COMP | | 0 | 0 | 31 | ABD | 6 | COMP | | 0 | 0 | 32 | ABD | 6 | COMP | | 0 | 0 | 33 | ABD | 6 | COM | | 0 | 0 | 34 | ABD | 6 | COMP | WHOLE ABDOMEN | 1550 | 0 | 35 | ABD | 6 | NCI | | 0 | 0 | 36 | ABD | 6 | LMB | | 0 | 0 | 37 | NP | 6 | ACOMP | | 0 | 0 | 38 | ABD | 6 | NCI | | 4000 | 0 |
| Average | | | | | 462 | 0 |
| NHNB | | | | | | | 39 | 0 | 7 | LSAL2 | | 0 | 0 | 40 | 0 | 7 | LSAL2/COM | BRAIN,TOT.LUNG | 3600 | 0 | 41 | 0 | 7 | LSAL2 | BRAIN,INV.Y | 5600 | 0 | 42 | 0 | 7 | COM | | 0 | 0 | 43 | 0 | 7 | LSAL2 | MEDIASTINUM | 750 | 0 | 44 | 0 | 7 | LSAL2 | MEDIASTINUM | 2000 | 0 | 45 | 0 | 7 | COMP | BRAIN | 2400 | 0 |
| Average | | | | | 2050 | 0 |
|
|
MOPP: nitrogen mustard, oncovin, prednisone, and procarbazine; COM/P: cyclophosphamide,oncovin, and methotrexate/prednisone; ABVD: adriamycin, bleomycin, vinblastine, and deticen; NCI: national cancer institute; ACOMP: like comp with adriamycine; LSA2L2: norma wollner protocol; LMB: no abbreviation; NS: nodular sclerosis; LP: lymphocyte predominance; MC: mixed cellularity; LD: lymphocyte depletion.
|